The Online Investor
MYGN Buyback image

Myriad Genetics, Inc. Buyback

OLI recorded this information on 11/19/2018

Company: Myriad Genetics, Inc.
Buyback: MYGN buyback
$Amount Authorized: $50,000,000
Buyback Details: Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase ("ASR") agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock. Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the company's board of directors.

Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology.

MYGN SEC Filing Email Alerts Service

Open the MYGN Page at The Online Investor »

Company Name: 
Myriad Genetics, Inc.
Stock buyback: 
MYGN buyback
Number of ETFs Holding MYGN: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the MYGN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Hold (1.50 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
MYGN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

MYGN Buyback Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.